Platinum resistance: the role of DNA repair pathways
- PMID: 18316546
- DOI: 10.1158/1078-0432.CCR-07-2238
Platinum resistance: the role of DNA repair pathways
Abstract
Although platinum chemotherapeutic agents such as carboplatin, cisplatin, and oxaliplatin are used to treat a broad range of malignant diseases, their efficacy in most cancers is limited by the development of resistance. There are multiple factors that contribute to platinum resistance but alterations of DNA repair processes have been known for some time to be important in mediating resistance. Recently acquired knowledge has provided insight into the molecular mechanisms of DNA repair pathways and their effect on response to chemotherapy. This review will discuss the most important DNA repair pathways known to be involved in the platinum response, i.e., nucleotide excision repair (NER) and mismatch repair (MMR), and will briefly touch on the role of BRCA in DNA repair. The therapeutic implications of alterations in DNA repair which affect response to platinum in the treatment of patients with malignant disease, such as excision repair cross-complementation group 1 (ERCC1) deficiency and mismatch repair deficiency, will be reviewed.
Similar articles
-
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.Cancer Treat Rev. 1998 Oct;24(5):331-44. doi: 10.1016/s0305-7372(98)90056-1. Cancer Treat Rev. 1998. PMID: 9861196 Review.
-
Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?Cancer Lett. 2014 May 1;346(2):163-71. doi: 10.1016/j.canlet.2014.01.005. Epub 2014 Jan 21. Cancer Lett. 2014. PMID: 24462818 Review.
-
Platinum drugs and DNA repair mechanisms in lung cancer.Anticancer Res. 2014 Jan;34(1):493-501. Anticancer Res. 2014. PMID: 24403507 Review.
-
Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.Clin Exp Pharmacol Physiol. 2014 Oct;41(10):817-24. doi: 10.1111/1440-1681.12282. Clin Exp Pharmacol Physiol. 2014. PMID: 25115435
-
Ongoing and unsaid on oxaliplatin: the hope.Br J Cancer. 1998 Jun;77 Suppl 4(Suppl 4):8-11. doi: 10.1038/bjc.1998.429. Br J Cancer. 1998. PMID: 9647613 Free PMC article. Review.
Cited by
-
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.J Gynecol Oncol. 2016 May;27(3):e31. doi: 10.3802/jgo.2016.27.e31. J Gynecol Oncol. 2016. PMID: 27029752 Free PMC article. Review.
-
Hypermethylation of lncRNA MEG3 impairs chemosensitivity of breast cancer cells.J Clin Lab Anal. 2020 Sep;34(9):e23369. doi: 10.1002/jcla.23369. Epub 2020 Jul 3. J Clin Lab Anal. 2020. PMID: 32618397 Free PMC article.
-
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.Br J Cancer. 2013 Apr 30;108(8):1695-703. doi: 10.1038/bjc.2013.127. Epub 2013 Apr 2. Br J Cancer. 2013. PMID: 23549037 Free PMC article. Clinical Trial.
-
A Significant Statistical Advancement on the Predictive Values of ERCC1 Polymorphisms for Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: An Updated Meta-Analysis.Dis Markers. 2016;2016:7643981. doi: 10.1155/2016/7643981. Epub 2016 Jan 21. Dis Markers. 2016. PMID: 27057082 Free PMC article. Review.
-
RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer.Acta Pharmacol Sin. 2016 Nov;37(11):1490-1498. doi: 10.1038/aps.2016.100. Epub 2016 Sep 26. Acta Pharmacol Sin. 2016. PMID: 27665847 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
